Drugs / C. difficile vaccine formulation 2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05805826 | Mar 2023 → Jun 2031 expected | Clostridium difficile colitis | Pfizer | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C. difficile vaccine formulation 2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05805826 ↗ |
| Modality | Vaccine | “C. difficile vaccine formulation 2 given as an intramuscular injection” NCT05805826 ↗ |
| Route | Intramuscular | “C. difficile vaccine formulation 2 given as an intramuscular injection” NCT05805826 ↗ |